Intermittent androgen suppression in prostate cancer: testosterone levels and its implication

Area of Science:

• Oncology
• Urology
• Endocrinology

Background:

• Intermittent androgen suppression (IAS) may mitigate side effects associated with continuous androgen ablation in prostate cancer patients.
• Prostate cancer treatment often involves androgen deprivation therapy, which can lead to significant side effects.

Purpose of the Study:

• To evaluate the impact of IAS on testosterone levels, quality of life (QOL), and sexual function in prostate cancer patients.
• To monitor patient outcomes during different phases of IAS therapy.

Main Methods:

• A prospective study involving 100 prostate cancer patients undergoing IAS in cycles.
• Treatment involved androgen blockade until prostate-specific antigen (PSA) nadir, followed by resumption at a PSA threshold of 10 ng/mL.
• Assessment included serum PSA, total testosterone, QOL scores, and sexual function (IIEF for sexually active patients).

Main Results:

• 46% of patients experienced low testosterone during the off-treatment phase; the rest recovered normal levels within a mean of 6.2 months.
• Quality of life worsened during active treatment but improved upon withdrawal, correlating with testosterone recovery.
• 54% of patients reported normal sexual function at therapy withdrawal, linked to the time of testosterone recovery.

Conclusions:

• Quality of life and sexual function appear to be closely linked to testosterone normalization following IAS.
• These findings suggest IAS is a viable treatment strategy with potential benefits for managing patient well-being during prostate cancer therapy.